Analysis of the gene coding for the BRCA2-interacting protein PALB2 in hereditary prostate cancer

Prostate

Volumn 68, Issue 6, 2008, Pages 675-678

  Tischkowitz, Marc ^a,b   Sabbaghian, Nelly ^a,b   Ray, Anna M ^c   Lange, Ethan M ^d   Foulkes, William D ^a,b,e   Cooney, Kathleen A ^c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF MICHIGAN   (United States)

^d IL   (United States)

^e MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

BRCA2; Hereditary prostate cancer; PALB2

Indexed keywords

BRCA2 PROTEIN;

ADULT; ARTICLE; FAMILIAL CANCER; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC CODE; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; ONSET AGE; PALB2 GENE; PRIORITY JOURNAL; PROSTATE CANCER;

ADENOCARCINOMA; ADULT; FATHERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PROSTATIC NEOPLASMS; SEQUENCE ANALYSIS, DNA; SIBLINGS; TUMOR SUPPRESSOR PROTEINS;

EID: 42949174531     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20729     Document Type: Article

References (26)

1. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 1992;89(8):3367-3371.
2. Gronberg H, Damber L, Damber JE. Familial prostate cancer in Sweden. A nationwide register cohort study. Cancer 1996;77(1):138-143.
3. Cui J, Staples MP, Hopper JL, English DR, McCredie MR, Giles GG. Segregation analyses of 1,476 population-based Australian families affected by prostate cancer. Am J Hum Genet 2001;68(5):1207-1218.
4. Matikaine MP, Pukkala E, Schleutker J, Tammela TL, Koivisto P, Sankila R, Kallioniemi OP. Relatives of prostate cancer patients have an increased risk of prostate and stomach cancers: A population-based, cancer registry study in Finland. Cancer Causes Control 2001;12(3):223-230.
5. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K. Environmental and heritable factors in the causation of cancer - Analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000;343(2):78-85.
6. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate 1990;17(4):337-347.
7. Simard J, Dumont M, Labuda D, Sinnett D, Meloche C, El-Alfy M, Berger L, Lees E, Labrie F, Tavtigian SV. Prostate cancer susceptibility genes: Lessons learned and challenges posed. Endocr Relat Cancer 2003;10(2):225-259.
8. Bruner DW, Moore D, Parlanti A, Dorgan J, Engstrom P. Relative risk of prostate cancer for men with affected relatives: Systematic review and meta-analysis. Int J Cancer 2003;107(5):797-803.
9. Kirchhoff T, Kauff ND, Mitra N, Nafa K, Huang H, Palmer C, Gulati T, Wadsworth E, Donat S, Robson ME, Ellis NA, Offit K. BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 2004;10(9):2918-2921.
10. Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P, Jackson R, Southgate C, Singh R, Falconer A, Dearnaley DP, Ardern-Jones A, Murkin A, Dowe A, Kelly J, Williams S, Oram R, Stevens M, Teare DM, Ponder BA, Gayther SA, Easton DF, Eeles RA. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 2003;72(1):1-12.
11. Tryggvadottir L, Vidarsdottir L, Thorgeirsson T, Jonasson JG, Olafsdottir EJ, Olafsdottir GH, Rafnar T, Thorlacius S, Jonsson E, Eyfjord JE, Tulinius H. Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst 2007;99(12):929-935.
12. Sinclair CS, Berry R, Schaid D, Thibodeau SN, Couch FJ. BRCA1 and BRCA2 have a limited role in familial prostate cancer. Cancer Res 2000;60(5):1371- 1375.
13. Wilkens EP, Freije D, Xu J, Nusskern DR, Suzuki H, Isaacs SD, Wiley K, Bujnovsky P, Meyers DA, Walsh PC, Isaacs WB. No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer. Prostate 1999;39(4):280-284.
14. Agalliu I, Kwon EM, Zadory D, McIntosh L, Thompson J, Stanford JL, Ostrander EA. Germline mutations in the BRCA2 gene and susceptibility to hereditary prostate cancer. Clin Cancer Res 2007;13(3):839-843.
15. Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, Liu X, Jasin M, Couch FJ, Livingston DM. Control of BRCA2 cellular and clinical functions by a nuclear partner, PA LB2. Mol Cell 2006;22(6):719-729.
16. Erkko H, Xia B, Nikkila J, Schleutker J, Syrjakoski K, Mannermaa A, Kallioniemi A, Pylkas K, Karppinen SM, Rapakko K, Miron A, Sheng Q, Li G, Mattila H, Bell DW, Haber DA, Grip M, Reiman M, Jukkola-Vuorinen A, Mustonen A, Kere J, Aaltonen LA, Kosma VM, Kataja V, Soini Y, Drapkin RI, Livingston DM, Winqvist R. A recurrent mutation in PALB2 in Finnish cancer families. Nature 2007;446(7133):316-319.
17. Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, Jayatilake H, McGuffog L, Hanks S, Evans DG, Eccles D, Easton DF, Stratton MR. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007;39(2):165-167.
18. Tischkowitz M, Xia B, Sabbaghian N, Reis-Filho JS, Hamel N, Li G, van Beers EH, Li L, Khalil T, Quenneville LA, Omeroglu A, Poll A, Lepage P, Wong N, Nederlof PM, Ashworth A, Tonin PN, Narod SA, Livingston DM, Foulkes WD. Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci USA 2007;104(16):6788-6793.
19. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res 2001;11(5):863-874.
20. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 2007;8(10):735-748.
21. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999;91(15):1310-1316.
22. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T, Jayatilake H, Ahmed M, Spanova K, North B, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR, Rahman N. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006;38(11):1239-1241.
23. Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, Kalb R, Neveling K, Kelly P, Seal S, Freund M, Wurm M, Batish SD, Lach FP, Yetgin S, Neitzel H, Ariffin H, Tischkowitz M, Mathew CG, Auerbach AD, Rahman N. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 2007;39(2):162-164.
24. Cybulski C, Huzarski T, Gorski B, Masojc B, Mierzejewski M, Debniak T, Gliniewicz B, Matyjasik J, Zlowocka E, Kurzawski G, Sikorski A, Posmyk M, Szwiec M, Czajka R, Narod SA, Lubinski J. A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res 2004;64(8):2677-2679.
25. Seppala EH, Ikonen T, Mononen N, Autio V, Rokman A, Matikainen MP, Tammela TL, Schleutker J. CHEK2 variants associate with hereditary prostate cancer. Br J Cancer 2003;89(10):1966-1970.
26. Wagenius M, Borg A, Johansson L, Giwercman A, Bratt O. CHEK2*1100delC is not an important high-risk gene in families with hereditary prostate cancer in southern Sweden. Scand J Urol Nephrol 2006;40(1):23-25.